Business Segments · Research and development expense
Medical — Research and development expense
Becton, Dickinson and Company Medical — Research and development expense remained flat by 0.0% to $130.75M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 17.0%, from $111.75M to $130.75M. Over 2 years (FY 2023 to FY 2025), Medical — Research and development expense shows an upward trend with a 8.4% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2023
Last reportedQ4 2025Nov 25, 2025
Rolls up toR&D
How to read this metric
Higher spending reflects a commitment to long-term growth and pipeline development, while lower spending may indicate a focus on short-term profitability.
Detailed definition
The total investment in research and development activities specifically allocated to the medical segment. This includes...
Peer comparison
Standard R&D investment reporting for medical technology firms.
Metric ID:
bdx_segment_medical_research_and_development_expenseHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $445M | $447M | $523M |
| YoY Change | — | +0.4% | +17.0% |
Range$445M – $523M
CAGR+8.4%
Avg YoY Growth+8.7%
Median YoY Growth+8.7%
Current Streak2+ years growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's medical — research and development expense?
- Becton, Dickinson and Company (BDX) reported medical — research and development expense of $130.75M in Q3 2025.
- How has Becton, Dickinson and Company's medical — research and development expense changed year-over-year?
- Becton, Dickinson and Company's medical — research and development expense increased by 17.0% year-over-year, from $111.75M to $130.75M.
- What is the long-term trend for Becton, Dickinson and Company's medical — research and development expense?
- Over 2 years (2023 to 2025), Becton, Dickinson and Company's medical — research and development expense has grown at a 8.4% compound annual growth rate (CAGR), from $445M to $523M.
- What does medical — research and development expense mean?
- Total spending on innovation and product development for the medical segment.